A randomized, double-blind, stratified, placebo-controlled, parallel-group study of the efficacy and safety of the ACAT inhibitor CD-505 [pactimibe] for reducing the progression of atherosclerosis in subjects with heterozygous familial hypercholesterolemia and carotid atherosclerosis using carotid ultrasound (CUS).

Trial Profile

A randomized, double-blind, stratified, placebo-controlled, parallel-group study of the efficacy and safety of the ACAT inhibitor CD-505 [pactimibe] for reducing the progression of atherosclerosis in subjects with heterozygous familial hypercholesterolemia and carotid atherosclerosis using carotid ultrasound (CUS).

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Pactimibe (Primary)
  • Indications Atherosclerosis; Hyperlipoproteinaemia type II
  • Focus Registrational; Therapeutic Use
  • Acronyms CAPTIVATE
  • Sponsors Daiichi Sankyo Inc
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 17 Jan 2012 Planned End Date (Mar 2006) added as reported by ClinicalTrials.gov.
    • 18 Mar 2009 Results published in JAMA: the Journal of the American Medical Association 301: 1131-1139, No. 11, 18 Mar 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top